UPDATE 2-Amgen drug meets goal for those with high genetic cholesterol

March 17, 2014 4:26 PM

28 0

March 17 (Reuters) - Amgen Inc said its experimental new type of cholesterol-fighting drug met the primary goal of a late-stage trial by slashing "bad" LDL cholesterol levels in patients with a genetic tendency towards high levels of the artery-clogging fat.

Amgen said on Monday patients given its injectable drug evolocumab once a month, on top of standard daily statin treatments, showed "clinically meaningful" improvement compared with taking statins alone after 12 weeks of treatment. The drug is also known as AMG-145.

Read more

To category page